Clinical trial
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
NCT01280695
Study timeline
Study start (unknown)2011-02-01Date precision: month
Registry last updated2014-04-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 2unresolved
Interventions
PlaceboDRUG
MSDC-0602 100 mgDRUG
MSDC-0602 250 mgDRUG
MSDC-0602 250 mgDRUG
PioglitazoneDRUG · verified · RxNorm: pioglitazone
Sponsors & collaborators
Metabolic Solutions Development Companylead sponsor
Mapped research locations
ChicagoIllinois, United States1Los AngelesCalifornia, United States1San AntonioTexas, United States1CincinnatiOhio, United States1AustinTexas, United States1Salt Lake CityUtah, United States1CharlestonSouth Carolina, United States1GreensboroNorth Carolina, United States1HialeahFlorida, United States1Pembroke PinesFlorida, United States1BradentonFlorida, United States1Chula VistaCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01280695 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.